Key facts
- This page summarizes Steven P. Coen's Form 4 filing for Ginkgo Bioworks Holdings, Inc. (DNA).
- 7 reported transactions and 3 derivative rows are listed below.
- Accepted by SEC: 21 Jul 2025, 16:28.
Steven P. Coen - 16 Jul 2025 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)
- Reporting relationship
- Chief Financial Officer and Chief Accounting Officer
- Issuer ticker
- DNA
- Reported as of
- 16 Jul 2025
- Net transaction value
- -$10,669
- SEC form
- 4
- Accepted by SEC
- 21 Jul 2025, 16:28:30 UTC
- Prior SEC filing
- 22 May 2025
- Next SEC filing
- 26 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Karen Tepichin, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven P. Coen filed Form 4 for Ginkgo Bioworks Holdings, Inc. (DNA) on 21 Jul 2025.
Change
- Previous filing in this sequence was filed on 22 May 2025.
- Current net transaction value: -$10,669.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0001977441
Primary reporting owner
Coen Steven P.
- Relationship
- Chief Financial Officer and Chief Accounting Officer
- Address
- C/O GINKGO BIOWORKS HOLDINGS, INC., 27 DRYDOCK AVENUE, BOSTON
- Signature
- /s/ Karen Tepichin, Attorney-in-Fact
- Signature date
- 21 Jul 2025
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
DNA
transaction
Class A Common Stock
Options Exercise
- Transaction value
- Shares
- +1,174
- Change %
- +13%
- Price
- Shares after
- 10,390
- Date
- 16 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
DNA
transaction
Class A Common Stock
Options Exercise
- Transaction value
- Shares
- +312
- Change %
- +3%
- Price
- Shares after
- 10,702
- Date
- 16 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
DNA
transaction
Class A Common Stock
Options Exercise
- Transaction value
- Shares
- +1,061
- Change %
- +9.9%
- Price
- Shares after
- 11,763
- Date
- 16 Jul 2025
- Ownership
- Direct
- Footnotes
- F1
DNA
transaction
Class A Common Stock
Sale
- Transaction value
- $10,669
- Shares
- -1,084
- Change %
- -9.2%
- Price
- $9.84
- Shares after
- 10,679
- Date
- 17 Jul 2025
- Ownership
- Direct
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
DNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -1,174
- Change %
- -8.3%
- Price
- Shares after
- 12,927
- Date
- 16 Jul 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 1,174
- Exercise price
- Footnotes
- F1, F3
DNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -312
- Change %
- -5.9%
- Price
- Shares after
- 5,003
- Date
- 16 Jul 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 312
- Exercise price
- Footnotes
- F1, F4
DNA
transaction
Derivative
Restricted Stock Units
Options Exercise
- Transaction value
- Shares
- -1,061
- Change %
- -33%
- Price
- Shares after
- 2,123
- Date
- 16 Jul 2025
- Ownership
- Direct
- Underlying class
- Class A Common Stock
- Underlying amount
- 1,061
- Exercise price
- Footnotes
- F1, F5
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 5 footnotes
Footnote F1
Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Class A Common Stock.
Footnote F2
Represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock and/or restricted stock units. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligations be funded by a "sell to cover" transaction.
Footnote F3
The RSUs vest as follows: 25% of the underlying shares vested on May 1, 2024, then 36 equal monthly installments thereafter.
Footnote F4
The RSUs vest as follows: 2/48ths of the underlying shares vested on May 1, 2024, then 46 equal monthly installments thereafter.
Footnote F5
The RSUs vest as follows: 25% vested on April 16, 2025; 25% vested on July 16, 2025; 25% will vest on October 16, 2025; and 25% will vest on January 16, 2026.
SEC remarks
Chief Financial Officer and Chief Accounting Officer